Trial · NCT01853982
Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia
NCT01853982, Phase 3, Terminated, Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); results first posted 2015-06-15
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia. Trials, record NCT01853982. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01853982
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia
- NCT number
- NCT01853982
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 4 participants, actual
- Lead sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Conditions
- Ventilator-Associated Pneumonia (VAP)
- Interventions
- Ceftolozane/Tazobactam, Piperacillin/Tazobactam
- First posted
- 2013-05-15
- Last updated
- 2018-11-16
- Results first posted
- 2015-06-15
- Limitations and caveats
- This study was electively terminated to focus on a larger registrational study, which was also part of the clinical development program for nosocomial pneumonia.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Clinical Response at the End of Therapy Visit | 24 hours after last dose of study drug |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Clinical Response at the End of Therapy Visit | 24 hours after last dose of study drug | There is no analysis population or data available for this measure. This study was electively terminated to focus on a larger registrational study, which was also part of the clinical development program for nosocomial pneumonia. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow8
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Ceftolozane/Tazobactam | 2 | |
| Overall Study | STARTED | Piperacillin/Tazobactam | 2 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Ceftolozane/Tazobactam | 2 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Piperacillin/Tazobactam | 2 | |
| Overall Study | COMPLETED | Ceftolozane/Tazobactam | 0 | |
| Overall Study | COMPLETED | Piperacillin/Tazobactam | 1 | |
| Overall Study | NOT COMPLETED | Ceftolozane/Tazobactam | 2 | |
| Overall Study | NOT COMPLETED | Piperacillin/Tazobactam | 1 |
Source ClinicalTrials.gov
Adverse events16
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Constipation | Gastrointestinal disorders | Ceftolozane/Tazobactam | 1 | 2 | 1 |
| other | Constipation | Gastrointestinal disorders | Piperacillin/Tazobactam | 0 | 2 | 0 |
| other | Urinary tract infection | Infections and infestations | Ceftolozane/Tazobactam | 1 | 2 | 1 |
| other | Urinary tract infection | Infections and infestations | Piperacillin/Tazobactam | 0 | 2 | 0 |
| other | Hypernatraemia | Metabolism and nutrition disorders | Ceftolozane/Tazobactam | 1 | 2 | 1 |
| other | Hypernatraemia | Metabolism and nutrition disorders | Piperacillin/Tazobactam | 0 | 2 | 0 |
| other | Anxiety | Psychiatric disorders | Ceftolozane/Tazobactam | 1 | 2 | 1 |
| other | Anxiety | Psychiatric disorders | Piperacillin/Tazobactam | 0 | 2 | 0 |
| other | Rash | Skin and subcutaneous tissue disorders | Ceftolozane/Tazobactam | 0 | 2 | 0 |
| other | Rash | Skin and subcutaneous tissue disorders | Piperacillin/Tazobactam | 1 | 2 | 1 |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Ceftolozane/Tazobactam | ||
| Total, all-cause mortality | Piperacillin/Tazobactam | ||
| Total, other adverse events | Ceftolozane/Tazobactam | 2 | 2 |
| Total, other adverse events | Piperacillin/Tazobactam | 1 | 2 |
| Total, serious adverse events | Ceftolozane/Tazobactam | 1 | 2 |
| Total, serious adverse events | Piperacillin/Tazobactam | 1 | 2 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Ceftolozane/Tazobactam vs Piperacillin/Tazobactam: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01853982
GET https://conductscience.org/api/trials/v1/NCT01853982/registered